Geoffrey Oxnard, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

GeoffreyRaymondOxnardMD

Oncology Boston, MA

Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Dr. Oxnard is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Oxnard's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Dana-Farber Cancer Institute, D1234
    Boston, MA 02215
    Phone(617) 632-6049
    Fax(617) 632-5786
  • Is this information wrong?

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2008 - 2011
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
  • University of Chicago Pritzker School of Medicine
    University of Chicago Pritzker School of MedicineClass of 2005

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - Present
  • MA State Medical License
    MA State Medical License 2007 - 2021
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis. 
    2019 ASCO Annual Meeting - 6/1/2019
  • SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung c... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Join now to see all

Authored Content

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

  • AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards
    AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) AwardsOctober 22nd, 2020
  • Over 50 Types of Cancer Diagnosed with New Blood Test
    Over 50 Types of Cancer Diagnosed with New Blood TestApril 6th, 2020
  • This New Blood Test Accurately Predicts 50 Types of Cancer
    This New Blood Test Accurately Predicts 50 Types of CancerApril 2nd, 2020
  • Join now to see all

Hospital Affiliations